Similar articles

• Use of interferon-beta in the treatment of multiple sclerosis.

  Derwenskus J, Lublin FD. Derwenskus J, et al. Adv Neurol. 2006;98:257-71. Adv Neurol. 2006. PMID: 16400838 Review. No abstract available.
• [Beta interferon and multiple sclerosis].

  Kinnunen E. Kinnunen E. Duodecim. 1996;112(24):2368-73. Duodecim. 1996. PMID: 10605237 Review. Finnish. No abstract available.
• Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.

  Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, Francis G; EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study Group; University of British Columbia MS/MRI Research Group. Schwid SR, et al. Arch Neurol. 2005 May;62(5):785-92. doi: 10.1001/archneur.62.5.785. Arch Neurol. 2005. PMID: 15883267 Clinical Trial.
• Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.

  Schwid SR, Panitch HS. Schwid SR, et al. Clin Ther. 2007 Sep;29(9):2031-48. doi: 10.1016/j.clinthera.2007.09.025. Clin Ther. 2007. PMID: 18035202 Clinical Trial.
• Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

  Sorensen PS, Bertolotto A. Sorensen PS, et al. Neurology. 2007 Oct 9;69(15):1552; author reply 1553. doi: 10.1212/01.wnl.0000285763.31151.a6. Neurology. 2007. PMID: 17923618 No abstract available.